J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

Alembic Pharmaceuticals has acquired UTILITY therapeutics, expanding its portfolio with the addition of Pivya to treat uUTIs.

The DoH and Children’s National Hospital in the US have signed a MoU to advance paediatric cell and gene therapy.

A discussion on formulation development, contract services, and some of the critical considerations when moving from molecule to clinic.

Biocon Biologics’ Denosumab biosimilars, Vevzuo and Evfraxy, have received marketing authorisation in the European Union (EU).

Proposals for drug exclusivities and feeble measures to combat drug shortages are unlikely to boost innovation, say some ...

The U.S. Food and Drug Administration’s (FDA’s) evolving guidance on Computer Software Assurance and AI/ML-Based Software ...

The FDA has approved Takeda’s new immunoglobulin therapy, Gammagard liquid ERC [immune globulin infusion (human)], to treat ...

A new podcast from industry experts MarketScan explains why social determinants of health are critical to patient care.

Piramal Pharma invests $90m to expand its two US facilities, enhancing manufacturing capabilities for sterile injectables and ...

The sale caps a difficult time for zilovertamab and ONCT-808 under Oncternal’s ownership. Zilovertamab was deprioritised by ...

AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous ...